Myriad Genetics, Inc. Announces First Quarter Fiscal 2009 Financial Results Conference Call

23 Oct 2008

·www.biospace.com

Financial Statement

SALT LAKE CITY, UT--(Marketwire - October 23, 2008) - Myriad Genetics, Inc. (NASDAQ: MYGN) has arranged a conference call with the management team to provide a company update. Peter D. Meldrum, President and Chief Executive Officer, will host the call along with Jim Evans, Chief Financial Officer, Gregory C. Critchfield, M.D., President of Myriad Genetic Laboratories, Inc., and Adrian N. Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc.

Organizations

Myriad Genetics, Inc.

UT Group Co., Ltd.Myriad Genetic Laboratories, Inc.

[+1]

Indications

Targets

Drugs

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.